SCHEMBL1050665

SCHEMBL1050665

COC(=O)c1ccc(CCN2C(=O)CCN2CCC(=O)C2CCC2)cc1

nearest known ligand 0.46

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
PTGER2 P43116 16/20 0.46
PTGER4 P35408 15/20 0.46
HRH1 P35367 2/20 0.41
KDM4E B2RXH2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1052742 0.82 PTGER2 (0.54) PTGER2PTGER4HRH1
SCHEMBL1058456 0.80 PTGER2 (0.54) PTGER2PTGER4
SCHEMBL1057413 0.80 PTGER2 (0.56) PTGER2PTGER4
SCHEMBL1055320 0.78 PTGER2 (0.57) PTGER2PTGER4
SCHEMBL4082485 0.78 PTGER2 (0.48) PTGER2PTGER4HRH1
SCHEMBL12930084 0.78 CYP4A11 (0.49) PTGER2PTGER4HRH1
SCHEMBL4082516 0.77 PTGER2 (0.44) PTGER2PTGER4
SCHEMBL1057599 0.76 PTGER4 (0.47) PTGER2PTGER4
SCHEMBL1056797 0.76 PTGER2 (0.79) PTGER2PTGER4
SCHEMBL1057133 0.75 PTGER2 (0.75) PTGER2PTGER4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7863312-B2 Pyrazolidinone compounds as ligands of the prostaglandin EP2 and/or EP4 receptors MERCK SERONO SA (CH) 2011-01-04 US disclosed
US-20080234346-A1 PYRAZALIDINONE COMPOUNDS AS LIGANDS OF THE PROSTAGLANDIN EP2 AND/OR EP4 RECEPTORS LABORATOIRES SERONO S.A. (CH) 2008-09-25 US disclosed
US-7410991-B2 Pyrazolidinone compounds as ligands of the prostaglandin EP2 and/or EP4 receptors LABORATOIRES SERONO S.A. (CH) 2008-08-12 US disclosed
EP-1439837-B1 PYRAZOLIDINONE COMPOUNDS AS LIGANDS OF THE PROSTAGLANDIN EP2 AND/OR EP4 RECEPTORS SERONO LAB (CH) 2008-04-09 EP disclosed
US-20040254233-A1 Pyrazolidinone compounds as ligands of the prostaglandin ep2 and/or ep4 receptors MERCK SERONO SA (CH) 2004-12-16 US disclosed
EP-1439837-A1 PYRAZOLIDINONE COMPOUNDS AS LIGANDS OF THE PROSTAGLANDIN EP2 AND/OR EP4 RECEPTORS Applied Research Systems ARS Holding N.V. (AN) 2004-07-28 EP disclosed
WO-2003035064-A1 PYRAZOLIDINONE COMPOUNDS AS LIGANDS OF THE PROSTAGLANDIN EP2 AND/OR EP4 RECEPTORS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2003-05-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254233-A1 Pyrazolidinone compounds as ligands of the prostaglandin ep2 and/or ep4 receptors PTGER4, PTGER2, PTGER1 PTGER2 2/4885PTGER4 1/4885HRH1 601/4885
US-20080234346-A1 PYRAZALIDINONE COMPOUNDS AS LIGANDS OF THE PROSTAGLANDIN EP2 AND/OR EP4 RECEPTORS PTGER4, PTGER2, PTGER1 PTGER2 2/4885PTGER4 1/4885HRH1 410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.